Hot Features
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-sm... Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0262 | -17.328042328 | 0.1512 | 0.1548 | 0.1216 | 2164359 | 0.13866603 | CS |
| 4 | -0.055 | -30.5555555556 | 0.18 | 0.3583 | 0.1216 | 22979561 | 0.22665083 | CS |
| 12 | -0.0825 | -39.7590361446 | 0.2075 | 0.3583 | 0.1216 | 10345442 | 0.21745558 | CS |
| 26 | -0.734 | -85.4481955763 | 0.859 | 2.83 | 0.1216 | 9082988 | 0.68934093 | CS |
| 52 | -12.175 | -98.9837398374 | 12.3 | 33.66 | 0.1216 | 4967472 | 1.04593931 | CS |
| 156 | -7.375 | -98.3333333333 | 7.5 | 33.66 | 0.1216 | 4510425 | 1.15524291 | CS |
| 260 | -7.375 | -98.3333333333 | 7.5 | 33.66 | 0.1216 | 4510425 | 1.15524291 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.